(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.08%) $78.17
(0.84%) $2.16
(-0.25%) $2 302.90
(0.04%) $26.70
(-0.56%) $959.90
(0.04%) $0.929
(-0.03%) $10.87
(0.02%) $0.797
(0.00%) $91.45
0.84% HKD 0.240
Live Chart Being Loaded With Signals
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China...
Stats | |
---|---|
Dzisiejszy wolumen | 216 000 |
Średni wolumen | 98 189.00 |
Kapitalizacja rynkowa | 487.89M |
EPS | HKD0 ( 2023-08-30 ) |
Last Dividend | HKD0.00980 ( 2023-05-31 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 24.00 |
ATR14 | HKD0 (0.00%) |
Sinco Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sinco Pharmaceuticals Finanse
Annual | 2022 |
Przychody: | HKD2.27B |
Zysk brutto: | HKD305.87M (13.47 %) |
EPS: | HKD0.0342 |
FY | 2022 |
Przychody: | HKD2.27B |
Zysk brutto: | HKD305.87M (13.47 %) |
EPS: | HKD0.0342 |
FY | 2021 |
Przychody: | HKD2.02B |
Zysk brutto: | HKD364.95M (18.03 %) |
EPS: | HKD0.0800 |
FY | 2020 |
Przychody: | HKD2.05B |
Zysk brutto: | HKD273.83M (13.36 %) |
EPS: | HKD0.0700 |
Financial Reports:
No articles found.
Sinco Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.00980 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00330 | 2016-09-09 |
Last Dividend | HKD0.00980 | 2023-05-31 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | HKD0.0131 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.34 | -- |
Div. Sustainability Score | 9.62 | |
Div.Growth Potential Score | 4.53 | |
Div. Directional Score | 7.08 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3759.HK | Ex Dividend Knight | 2023-07-18 | Annually | 0 | 0.00% | |
1666.HK | Ex Dividend Knight | 2023-06-19 | Annually | 0 | 0.00% | |
0700.HK | Ex Dividend Knight | 2023-05-19 | Annually | 0 | 0.00% | |
2230.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
1234.HK | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
0297.HK | Ex Dividend Junior | 2023-06-23 | Sporadic | 0 | 0.00% | |
3996.HK | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% | |
1798.HK | Ex Dividend Junior | 2023-07-06 | Sporadic | 0 | 0.00% | |
0831.HK | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
2382.HK | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0122 | 1.500 | 9.76 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0165 | 1.200 | 9.45 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0449 | 1.500 | -0.612 | -0.919 | [0.1 - 1] |
payoutRatioTTM | 0.668 | -1.000 | 3.32 | -3.32 | [0 - 1] |
currentRatioTTM | 1.183 | 0.800 | 9.08 | 7.27 | [1 - 3] |
quickRatioTTM | 0.818 | 0.800 | 9.90 | 7.92 | [0.8 - 2.5] |
cashRatioTTM | 0.517 | 1.500 | 8.24 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.125 | -1.500 | 7.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.203 | 2.00 | 9.93 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.180 | 2.00 | 9.91 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.339 | -1.500 | 8.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.119 | 1.000 | -1.345 | -1.345 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0343 | 1.000 | -1.314 | -1.314 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.01 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 1.359 | 0.800 | 4.27 | 3.42 | [0.5 - 2] |
Total Score | 9.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 16.64 | 1.000 | 8.42 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0449 | 2.50 | -0.394 | -0.919 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.180 | 2.00 | 9.94 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.41 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.203 | 2.00 | 9.93 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.668 | 1.500 | 3.32 | -3.32 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.185 | 1.000 | 7.87 | 0 | [0.1 - 0.5] |
Total Score | 4.53 |
Sinco Pharmaceuticals
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products; and offers international trade services, as well as provides consultation services for medical and biological technology. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej